Garo Armen, Ph.D.Chairman of the Board
Garo serves as Chairman and Chief Executive Officer of Agenus Inc., and Chairman of the Board of AgenTus.
Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products for 20 years.
Walter Flamenbaum, M.D.Vice-chairman
Dr. Flamenbaum is a Managing Director of The Channel Group since 2014. Prior to that he was the Founding Partner of Paul Capital Healthcare Funds, which has invested over $1 billion in forty investments, and was a Partner Emeritus at Paul Capital. He led the development and refinement of its investment strategy, processes and techniques, as well as actively participating in the majority of the Fund’s investments, including roles in sourcing, negotiating, structuring and other activities. Dr. Flamenbaum’s broad based medical knowledge and investment experience provided the Fund with a unique resource for healthcare royalty and revenue investing. He was primarily responsible for the development of the diverse team of healthcare and financial investment professionals, allowing for the Fund’s development and successes. Dr. Flamenbaum has more than 40 years of healthcare experience, including the development and evaluation of pharmaceutical and biotechnology based-drugs, medical devices and diagnostics. During the 10 years prior to joining Paul Capital Partners in 1999, he had extensive experience in the licensing of healthcare product-related intellectual properties and the assessment of the develop of healthcare and in healthcare investing opportunities. Prior to Paul Capital he founded a contract research organization, started a biomedical company, and had senior management responsibilities in a biotechnology company. These activities provided him with a broad and well developed base in healthcare product development and commercialization. He has been board certified in internal medicine, nephrology and clinical pharmacology and was a professor of medicine at the Mt. Sinai School of Medicine and Tufts University School of Medicine. Dr. Flamenbaum served in the U.S. Army at the Walter Reed Army Institute of Research and the Walter Reed Army Medical Center from 1970 until 1976. He completed his training in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in nephrology at the Peter Bent Brigham Hospital. He earned his M.D. from Columbia University’s College of Physicians & Surgeons and his B.A. from Washington & Jefferson College.
Mr. Corvese is president and founder of Vencor Capital, a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to Vencor, Mr. Corvese worked on investments in the US and global equity markets as a managing director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management, a $25-billion money management firm. While at Chancellor, Mr. Corvese was a portfolio manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founding and managing his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert as an equity analyst following the chemical and specialty chemical industries and he participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor.
Mr. Corvese currently serves on the board of the National Telecommunications Company, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.
Mr. Wiinberg has 20 years of senior leadership experience, currently serving as Chief Executive Officer of X+Vax Technology A.S., a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Mr. Wiinberg previously served as Chief Executive Officer of H. Lundbeck A.S., a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. His expertise encompasses serving on the boards of several other healthcare industry associations and multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies, acquired by Pfizer in 2009.
John Baldoni, Ph.D.Director
John has over 40 years of experience in the pharmaceutical industry. He spent 29 years at GSK R&D including 11 years on its Executive Leadership Team; leading its Platform Technology and Science organization which comprised about 40% of R&D headcount. In this role, his organization supported development of small molecules, biopharmaceuticals and cell and gene therapy modalities. Most recently John was the Chief Technology Officer of Integral, a biotech formed to integrate healthcare data, computation, and science to redefine the drug discovery and development process. John has participated in the research and development of scores of commercial products. Currently, John is an independent consultant, President of Scinovo Consulting LLC and is an advisor to several emerging technology companies. He is a proponent of seeking, integrating and implementing innovative approaches to drug discovery and development. He conceptualized and is currently Senior Science Advisor to the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium – an open membership, public/private partnership currently comprised of Pharma, Tech, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. John was Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention, and innovation in artificial intelligence. John received his PhD from Penn State University in biological chemistry in 1980.